ATE279921T1 - Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache - Google Patents

Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache

Info

Publication number
ATE279921T1
ATE279921T1 AT00905615T AT00905615T ATE279921T1 AT E279921 T1 ATE279921 T1 AT E279921T1 AT 00905615 T AT00905615 T AT 00905615T AT 00905615 T AT00905615 T AT 00905615T AT E279921 T1 ATE279921 T1 AT E279921T1
Authority
AT
Austria
Prior art keywords
cluster headache
anticonvulsive
derivatives
treat cluster
treat
Prior art date
Application number
AT00905615T
Other languages
English (en)
Inventor
Enrique Carrazana
Steve D Wheeler
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE279921T1 publication Critical patent/ATE279921T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT00905615T 1999-01-19 2000-01-13 Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache ATE279921T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11638899P 1999-01-19 1999-01-19
PCT/US2000/000919 WO2000042996A2 (en) 1999-01-19 2000-01-13 Use of anticonvulsant derivatives for treating cluster headaches

Publications (1)

Publication Number Publication Date
ATE279921T1 true ATE279921T1 (de) 2004-11-15

Family

ID=22366884

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00905615T ATE279921T1 (de) 1999-01-19 2000-01-13 Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache

Country Status (24)

Country Link
US (1) US6319903B1 (de)
EP (1) EP1143967B1 (de)
JP (1) JP2002535270A (de)
KR (1) KR100653326B1 (de)
CN (1) CN1182845C (de)
AT (1) ATE279921T1 (de)
AU (1) AU771388B2 (de)
BR (1) BR0008176A (de)
CA (1) CA2359541C (de)
CZ (1) CZ20012620A3 (de)
DE (1) DE60015070T2 (de)
DK (1) DK1143967T3 (de)
ES (1) ES2228465T3 (de)
HU (1) HUP0105154A3 (de)
IL (2) IL144406A0 (de)
MX (1) MXPA01007350A (de)
MY (1) MY121486A (de)
NO (1) NO20013554L (de)
NZ (1) NZ513115A (de)
PT (1) PT1143967E (de)
TR (1) TR200102711T2 (de)
TW (1) TWI248360B (de)
WO (1) WO2000042996A2 (de)
ZA (1) ZA200106786B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
DK1311256T3 (da) * 2000-08-17 2005-11-28 Teva Pharma Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
RU2004126093A (ru) * 2002-02-26 2005-04-10 Орто-Макнейл Фармасьютикал, Инк. (Us) Комбинированная терапия для лечения мигрени, включающая применение производных противосудорожных средств и средств от мигрени
AU2003213719A1 (en) 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20070021356A1 (en) * 2002-03-18 2007-01-25 Cady Roger K Preemptive prophlyaxis of migraine
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
IL165383A0 (en) 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
EP1626707A4 (de) * 2003-02-05 2009-07-01 Yissum Res Dev Co Formulierung von n-(2-propylpentanoyl)-glycinamid mit verzögerter freisetzung und verwandten verbindungen
US20040176463A1 (en) * 2003-02-05 2004-09-09 Daniella Licht Immediate release formulation of n-(2-propylpentanoyl)glycinamide
US6949518B1 (en) 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
DE602005008084D1 (de) * 2004-08-24 2008-08-21 Janssen Pharmaceutica Nv Als antikonvulsive mittel geeignete neue benzokondensierte heteroarylsulfamidderivate
US20110117070A1 (en) * 2005-04-19 2011-05-19 Aurora Sheena K Compositions and methods for treating headache
US20060233892A1 (en) * 2005-04-19 2006-10-19 Curt Hendrix Topiramate compositions for treatment of headache
KR20080012360A (ko) * 2005-05-20 2008-02-11 얀센 파마슈티카 엔.브이. 설파미드 유도체의 제조 방법
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
EA200870556A1 (ru) * 2006-05-19 2009-06-30 Янссен Фармацевтика Н.В. Комбинированная терапия в лечении эпилепсии и родственных расстройств
WO2008027557A2 (en) 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US8298576B2 (en) 2006-11-17 2012-10-30 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
MX2009003911A (es) 2006-12-04 2009-05-28 Supernus Pharmaceuticals Inc Formulaciones de liberacion inmediata, mejoradas de topiramato.
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
EA018567B1 (ru) 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
CN102579367B (zh) 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
EP2829270B1 (de) 2012-03-23 2020-11-11 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Verbindungsprodukt mit synephrin und topiramat
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
EP3883546A1 (de) 2018-11-21 2021-09-29 Rosemont Pharmaceuticals Ltd Orale topiramat-suspensionsformulierungen mit verlängerter lagerstabilität und verbesserter bioverfügbarkeit
EP4297727A4 (de) * 2021-02-24 2024-12-25 NBO Pharma Inc. Verfahren und therapeutische kombinationen zur behandlung von idiopathischer intrakranialer hypertonie und clusterkopfschmerzen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
CA2267945C (en) * 1996-10-08 2005-05-17 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating neuropathic pain

Also Published As

Publication number Publication date
CN1352555A (zh) 2002-06-05
ES2228465T3 (es) 2005-04-16
PT1143967E (pt) 2005-01-31
CA2359541A1 (en) 2000-07-27
EP1143967A2 (de) 2001-10-17
IL144406A (en) 2006-08-20
TWI248360B (en) 2006-02-01
BR0008176A (pt) 2001-11-06
AU771388B2 (en) 2004-03-18
HUP0105154A3 (en) 2004-10-28
CZ20012620A3 (cs) 2002-09-11
NZ513115A (en) 2004-11-26
MXPA01007350A (es) 2003-06-06
MY121486A (en) 2006-01-28
DE60015070D1 (de) 2004-11-25
DE60015070T2 (de) 2006-01-05
TR200102711T2 (tr) 2001-12-21
CN1182845C (zh) 2005-01-05
IL144406A0 (en) 2002-05-23
NO20013554D0 (no) 2001-07-18
AU2726800A (en) 2000-08-07
EP1143967B1 (de) 2004-10-20
ZA200106786B (en) 2002-11-18
WO2000042996A2 (en) 2000-07-27
NO20013554L (no) 2001-07-18
HUP0105154A2 (hu) 2002-04-29
WO2000042996A3 (en) 2000-12-07
JP2002535270A (ja) 2002-10-22
KR100653326B1 (ko) 2006-12-04
KR20010101595A (ko) 2001-11-14
US6319903B1 (en) 2001-11-20
CA2359541C (en) 2005-06-21
DK1143967T3 (da) 2005-01-10

Similar Documents

Publication Publication Date Title
ATE279921T1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
DE60024660D1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
ATE365042T1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE253383T1 (de) Behandlung von in der luft enthaltenen mikroorganismen
DE69929464D1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
ATE275400T1 (de) Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ATE271865T1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
ATE345811T1 (de) Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen
ATE353667T1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
DE69912743D1 (de) Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)-aktivierungsweges
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
ATE234614T1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
ATE267608T1 (de) Verwendung von fsh zur behandlung von infertilität
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
ATE255892T1 (de) Verwendung von antikonvulsiven derivaten zur behandlung von bulimia nervosa
EP1102599A4 (de) Protease hemmstoffe zur verwendung in der behandlung von psoriasis
DE60137506D1 (de) Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose
SE0003126D0 (sv) Method of treatment
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1143967

Country of ref document: EP

REN Ceased due to non-payment of the annual fee